Amprologix secures £740,000 investment to accelerate development of…
22 October 2025Amprologix has raised £740,000 to accelerate the development of our breakthrough antibiotic Epidermicin NI01. This investment also supports our AI-driven…
Amprologix has raised £740,000 to accelerate the development of our breakthrough antibiotic Epidermicin NI01. This investment also supports our AI-driven…
We are pleased to announce that Professor Mat Upton, Chief Scientific Officer at Amprologix, will represent the company at the…
This summer we’ve been pleased to welcome Rutendo Mupfumi from the University of Plymouth to the Amprologix lab. As part…
Amprologix joins a global network of innovators We're proud to announce that Amprologix is one of the 103 finalists selected…
Mat Upton, CSO, presented the latest results from ongoing research at ESCMID Global 2025. ESCMID Global 2025 - the Congress of…
Amprologix has raised £740,000 to accelerate the development of our breakthrough antibiotic Epidermicin NI01. This investment also supports our AI-driven antimicrobial discovery platform, reinforcing our mission to tackle global antimicrobial resistance by developing novel antimicrobials.
We are pleased to announce that Professor Mat Upton, Chief Scientific Officer at Amprologix, will represent the company at the upcoming LSX World Congress in Boston, MA, USA
Amprologix joins a global network of innovators We're proud to announce that Amprologix is one of the 103 finalists selected to participate in the MassChallenge Switzerland & UK Accelerator Programme 2025, chosen from a pool of 1,527 high-potential startups worldwide. This milestone places Amprologix among a global community of science-driven innovators who are committed to […]
Amprologix will be attending the Investival Showcase in London on 18th November 2024 Amprologix will be attending the Investival Showcase in London on 18th November 2024. We look forward to meeting industry partners and investors who share our passion for developing new treatments to combat the rising global threat from antimicrobial resistance, including superbugs like MRSA and VRE. For […]
